Humacyte, Inc. (HUMA) stock
HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.50−0.04 (-7.27%)
Close on Nov 17, 2026Market cap $139.18MP/E –Yield –
Humacyte pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Humacyte's pe ratio was 7.9× on Jan 31, 2023.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2023 | Jan 31, 2023 | 7.9× | +1.6 |
| 2022 | Dec 30, 2022 | 6.3× | – |
See a number that looks wrong?